Endothelial Function and Progenitor Cells in Acute Ischemic Stroke (EPCAS)
Recruitment status was Recruiting
The purpose of this study is to determine whether levels of circulating endothelial progenitor cells (cEPC) are increased in the acute phase of ischemic stroke.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Endothelial Function and Progenitor Cells in Acute Ischemic Stroke|
- Levels of cEPC [ Time Frame: <48h, day 4-5, discharge or day 7 ] [ Designated as safety issue: No ]Levels of cEPC (CD34+/CD133+/VEGF2R+/CD31) in % of mononuclear cells using flow cytometry with respect to stroke subtypes.
- Levels of EMP [ Time Frame: <48h, day 4-5, day 7 or discharge ] [ Designated as safety issue: No ]Levels of EMP (Annexin V+/CD31+; CD62E+) using flow cytometry with respect to stroke subtypes.
- ENDOPAT [ Time Frame: <48h, day 4-5,day 7 ] [ Designated as safety issue: No ]Digital pulse volume change (with RH PAT as non invasive measurement (PAT-ratio; ENDOPAT, Itamar Medical Ltd.) for non-invasive, peripheral endothelial function
Biospecimen Retention: Samples Without DNA
whole blood, serum, PBMC, plasma
|Study Start Date:||July 2010|
|Estimated Study Completion Date:||June 2012|
|Estimated Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
first-ever ischemic stroke
first-ever ischemic stroke according to the WHO definition
Endothelial dysfunction is a key component of atherosclerosis which contributes to the development of cardio- and cerebrovascular diseases. However, endothelial dysfunction (ED) is not established as a risk factor for ischemic stroke.
As a novelty the proposed trial investigates the following variety of indirect markers of endothelial function in acute ischemic stroke:
circulating endothelial progenitor cells (EPC), endothelial microparticles (EMP), ENDOPAT (RH- PAT ratio) in two regards:
- time after ischemic events (< 48h, Days 4-5, day 7 or at discharge)
- etiological stroke subtypes
It is not known whether these parameters are changed after acute cerebral ischemia and could possibly serve as specific target for treatment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01289795
|Contact: Thomas Liman, MDemail@example.com|
|Contact: Matthias Endres, MDfirstname.lastname@example.org|
|Center for Stroke Research Berlin||Recruiting|
|Berlin, Germany, 10117|
|Contact: Thomas Liman, MD 004930450560643 email@example.com|
|Principal Investigator: Thomas Liman, MD|
|Principal Investigator:||Matthias Endres, MD||Center for Stroke Research Berlin|